Genomewide-association studies have revealed that SNPs (single nucleotide polymorphisms) in FTO (fat mass and obesityassociated) are robustly associated with BMI (body mass index) and obesity. FTO is an Fe(II) 2-OG (2-oxoglutarate)-dependent dioxygenase that can demethylate 3-meT (3-methylthymine) in single-stranded DNA, as well as 3-meU (3-methyluracil) and N6-methyl adenosine in RNA. In the present paper we describe the development of an RNase-cleavage assay measuring the demethylation activity of FTO on 3-meU. RNase A cleaves at the 3 -end of pyrimidines, including uracil, and a methyl group at position three of uracil inhibits cleavage. An oligonucleotide probe was designed consisting of a DNA stem, an RNA loop containing a single 3-meU as the only RNase A-cleavage site, a fluorescent reporter on one end and a quencher at the other end. FTO demethylation of the unique 3-meU enables RNase A cleavage, releasing the quencher and enabling a fluorescent signal. In the presence of excess RNase A, FTO activity is limiting to the development of fluorescent signal, which can be read continuously and is able to discriminate between wild-type and the catalytically dead R316Q FTO. 2-OG is a co-substrate of FTO and, as a metabolite in the citric acid cycle, is a marker of intracellular nutritional status. The assay described in the present paper was used to measure, for the first time, the K m of FTO for 2-OG. The K m of 2.88 μM is up to 10-fold lower than the estimated intracellular concentrations of 2-OG, rendering it unlikely that FTO functions as a sensor for 2-OG levels.
INTRODUCTION
In 2007, GWAS (genomewide-association studies) revealed that SNPs (single nucleotide polymorphisms) within intron 1 of FTO (fat mass and obesity-associated) are robustly associated with BMI (body mass index) and obesity [1] . Many subsequent studies, covering more than 22 distinct populations of European, African and Asian ancestries, have confirmed the association of FTO with BMI (reviewed in [2] ). It is clear from the weight of evidence that the major effect of SNPs in FTO is on increased energy intake, with a reduction in satiety.
FTO is widely expressed across multiple tissues, although it is most highly expressed in the brain, especially in the hypothalamus, a region that plays a key role in the control of energy homoeostasis [3] . We have found that expression of FTO, specifically in the ARC (arcuate nucleus) of the hypothalamus, is bi-directionally regulated as a function of nutritional status; decreasing following a 48 h fast and increasing after 10 weeks of exposure to a high-fat diet, and that modulating FTO levels specifically in the ARC can influence food intake [3, 4] . FTO shares sequence motifs with Fe(II)-and 2-OG (2-oxoglutarate)-dependent oxygenases. In vitro, recombinant FTO is able to catalyze the Fe(II)-and 2-OG-dependent demethylation of 3-meT (3-methylthymine) in single-stranded DNA [3] , as well as 3-meU (3-methyluracil) [5] and 6-meA (6-methyladenosine) [6] in single-stranded RNA, with concomitant production of succinate, formaldehyde and carbon dioxide, suggesting a potential role for FTO in nucleic acid repair or modification. Its selectivity for single-stranded over double-stranded nucleic acids, which could be predicted from its crystal structure [7] and has also been demonstrated empirically [5] , suggests that RNA would be its prime substrate. Because 2-OG, a key intermediate in the citric acid cycle, is a co-substrate of FTO, it is possible that FTO functions as a sensor for intracellular concentrations of this metabolite and thus cellular metabolism. However, the sensitivity of FTO to the concentration of 2-OG has not been measured and it remains unknown whether FTO activity is likely to be modulated by physiological variation in its the concentration of the substrate.
The SNP-bearing obesity-associated alleles of FTO are highly prevalent, thus altered FTO function has the potential to affect the body weight of up to 1 billion people. This has engendered considerable interest in the biochemical activity of FTO and has raised the spectre of modifying this activity for therapeutic purpose. Current assays of FTO function are all end-point assays that rely on radioactive tracers or HPLC detection of substrate and products [3, 5, 6, 8] . They require large amounts of purified FTO enzyme, are time-consuming and of limited utility in measuring enzyme kinetics. We set out to develop a microlitrescale, continuous, homogenous, fluorescence-based assay, suited to analysis of enzyme kinetics and high-throughput screens, and applied our assay to examine the enzyme kinetics of FTO with regards to its usage of 2-OG.
EXPERIMENTAL Recombinant wild-type and mutant FTO purification
Recombinant wild-type and mutant FTO proteins were purified as described previously [8, 9] . Briefly, expression plasmids were transformed into Escherichia coli BL21-Gold (DE3) (Stratagene) and cultured in LB (Luria-Bertani) broth and 50 μg/ml carbenicillin to a D 600 value of 1.0 at 37
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of the cloned gene was induced by the addition of 0.5 mM IPTG (isopropyl-β-D-1-thiogalactopyranoside) at 15
• C for 4 h. The cells were harvested and pellets were stored at − 80
• C until the day of the protein purification. Cell pellets were resuspended in lysis buffer [50 mM Hepes/KOH (pH 8.0), 2 mM 2-mercaptoethanol, 5 % glycerol and 300 mM NaCl] before digestion with lysozyme (1 mg/ml). Following sonication, the lysate was collected after centrifugation at 15 000 g for 30 min at 4
• C. The cleared lysate was supplemented with imidazole (final concentration 10 mM) before mixing with 1 ml of prewashed Ni-NTA (Ni 2 + -nitrilotriacetate) beads (Qiagen). After binding for 1 h in the cold, the mixture was re-loaded on to the column and washed three times with 10 ml each of lysis buffer supplemented with 10 mM imidazole, followed by 7.5 ml of lysis buffer supplemented with 40 mM imidazole. FTO was finally eluted with 2 ml of lysis buffer containing 250 mM imidazole. The eluate was concentrated with a 30 kDa MWCO (molecular-mass cut-off) concentrator (Sartorius Stedim) with buffer changing to 20 mM Hepes/KOH (pH 8), 5 % glycerol and 50 mM NaCl. Purified proteins were snap-frozen and stored at − 80
• C. Protein purity was estimated by Commassie Blue staining after resolving by SDS/PAGE (4-12 % gradient gels; Invitrogen).
FTO 3-meU demethylation assay
The stem-loop substrate containing a methylated uridine at the N-3 position was manufactured by the Midland Certified Reagent Company. Upon arrival, the substrate was re-suspended in nuclease-free water to a concentration of 100 μM and stored at − 80
• C. An optimal RNase A concentration was determined before assaying FTO demethylation activity. The fluorescent FTO demethylation activity assay was modified from our previously used assay using 14 C-labelled 3-methylthymidinelabelled DNA substrate, as reported previously [8, 9] . After initial optimization testing, any interference on the fluorescence signal from components, in each reaction, 100 nM of either methylated or unmethylated substrate was mixed with 75 μM Fe(NH 4 ) 2 (SO 4 ) 2 , 300 μM 2-OG, 2 mM ascorbate, 50 μg/ml BSA and various amount of RNase A from 10 − 12 μg/μl to 0.1 μg/μl in 50 mM Tris/HCl buffer at pH 7.0. Samples were prepared in duplicate and the FAM (6-carboxyfluorescein) emission was measured for 30 min at a wavelength of either 520 nm or 535 nm (depending on the plate reader) with excitation at 485 nm. The measurement was performed using a microplate reader [BMG Pherastar (520 nm), Labtech, or Infinite f500 (535 nm), Tecan] in a dark flat-bottomed 96-well plate at room temperature (25 • C). Similarly to the previous set up, 100 nM of the methylated substrate was incubated with the reaction mix with 625 pg of RNase A per reaction. Various concentrations of FTO were added from 0 to 1000 nM. Samples were prepared in duplicate and the FAM emission was measured for 30 min at a wavelength of 535 nm with excitation at 485 nm. The measurement was performed using a Tecan Infinite f500 microplate reader in a dark flat-bottomed 96-well plate at room temperature.
Data and statistical analyses
The experiments in 
RESULTS

Principle of the RNase-cleavage fluorescence assay
RNase A selectively cleaves the phosphodiester bond 3 of unpaired pyrimidine residues [10] . The co-crystal structure of RNaseA and 3 UMP suggested that a methyl group on N3 of the uracil base (3-meU) would inhibit the ability of RNase A to cleave [11] and that this feature could be exploited to develop an assay for FTO activity. To this end, we have engineered a stem-loop structure, where the stem is formed from DNA (to prevent cleavage by RNase A) and the loop from RNA, with the sole pyrimidine being a 3-meU in the middle of the loop. At one end of the probe is a FAM fluorescent reporter and at the other end is BHQ1 (blackhole quencher 1), which are held in close proximity to one another by the stem structure ( Figure 1A ). We and others have found that a stem-loop structure, as opposed to a linear RNA fragment, reduced background fluorescence, thereby increasing the signal-to-noise ratio [12] [13] [14] . Thus we expected that by demethylating the sole 3-meU on the loop of the probe, FTO would create a cleavage site for RNase A. Cleavage of the probe would destabilize the stem, separating the quencher from the fluorophore de-repressing the fluorescent signal. In the presence of an excess of RNase A FTO activity would become the rate-limiting step in the development of the fluorescent signal. An otherwise identical unmethylated probe would test these assumptions as its fluorescence would be RNase A-dependent, but independent of FTO.
3-meU is a poor substrate for RNase A
To test the prediction that a methyl group on the third position of uracil would inhibit the ability of RNase A to cleave, we performed a dose-response experiment comparing the ability of different concentrations of RNase A to cleave both the methylated and the unmethylated substrate. After initial optimization testing any interference on the fluorescence signal from components (Supplementary Figure S1 at http://www.BiochemJ. org/bj/444/bj4440183add.htm), in each reaction, 100 nM of either methylated or unmethylated substrate was mixed with 75 μM Fe(NH 4 ) 2 (SO 4 ) 2 , 300 μM 2-OG, 2 mM ascorbate, 50 μg/ml BSA and increasing amounts of RNase A from 10 − 12 μg/μl to 0.1 μg/μl in 50 mM Tris/HCl buffer at pH 7.0. Samples were prepared in duplicate and the FAM emission was measured for 30 min at a wavelength of 520 nm with excitation at 485 nm. At a concentration of 62.5 pg/μl RNAase A, there was selectivity for the unmethylated substrate over the methylated substrate, confirming the prediction ( Figure 1B) . We therefore selected a concentration of 62.5 pg/μl RNase A for all of the subsequent experiments.
FTO at 1μM gives maximum activity
Next we performed a dose-response experiment to identify the concentration of FTO that would give us the maximum response. As described above, 100 nM of the methylated substrate was incubated with the reaction mix with 62.5 pg/μl RNase A, while FTO was introduced in increasing concentrations from 0 to 1000 nM. FAM emission was measured for 30 min at a wavelength of 535 nm with excitation at 485 nm, and the rate of the initial reaction was calculated by a linear fit. We found that a concentration of 1 μM FTO resulted in the maximum reaction rate (Figure 2A ).
The FTO demethylation reaction is 2-OG-dependent and partially dependent on Fe(II)
In order to confirm that the fluorescence signal produced from the reaction was specific to FTO, we performed a number of controls. Using a systematic removal of individual components, we found that the production of a fluorescence signal was entirely dependent upon the presence of 2-OG, ascorbate and RNase A, whereas removal of Fe(II) reduced the signal produced ( Figure 2B ). Additionally, replacing FTO with an equivalent amount of BSA in the reaction mixture did not produce any signal above background levels. RNase A by itself did produce a background fluorescence signal, increasing over time, indicating that RNase A was still able to cleave after 3-meU, albeit at a far lower rate ( Figure 2B ).
The assay is able to distinguish between wild-type and mutant R316Q FTO
With all of the components in place, we were able to perform the assay with increasing concentrations of FTO increasing the rate of reaction. When we assayed the activity of a known mutation of FTO, R316Q, which we have previously reported to be catalytically inactive [8] , the rate of reaction in response to increasing concentrations of enzyme was equivalent to that of the BSA control (Figure 3 ). Thus our novel assay can distinguish between wild-type and a known FTO mutant.
Measuring the K m of 2-OG for FTO
Because 2-OG, a key intermediate in the citric acid cycle, is a cosubstrate of FTO, it is possible that FTO functions as a sensor for intracellular concentrations of this metabolite and thus cellular metabolism. We then used this assay to examine the enzyme kinetics of FTO with regard to its usage of 2-OG. As described above, 100 nM of the methylated substrate was incubated with the reaction mix with 625 pg of RNase A per reaction and 1 μM FTO, while increasing concentrations of 2-OG from 0 to 600 μM was introduced. FAM emission was measured for 30 min at a wavelength of 535 nm with excitation at 485 nm. FTO responds to 2-OG, consistent with Michaelis-Menten kinetics, with the K m for 2-OG calculated to be 2.88 μM (Figure 4 ).
DISCUSSION
FTO is the first and most robust of the so-called 'post-GWAS' obesity genes, with SNPs in its first intron being associated with increased BMI and risk for obesity. It is important to note that, as yet, no conclusive link has been made between the risk alleles and expression or function and FTO. Certainly, the weight of evidence from a multitude of animal models where FTO expression has been perturbed indicates some role for FTO in energy homoeostasis [4, [15] [16] [17] [18] . However, the physiological role of FTO and how this might link to the regulation of body weight has yet to be determined. With the aim of understanding more about its biochemistry, we have successfully developed a fluorescence RNase-cleavage assay for FTO.
Enzyme kinetics
A key aim in developing this assay was to ensure a rapid way of testing the function of any further human FTO mutations we might identify. We have done this previously at great cost and effort using a radioactive-based assay [8, 9] . In this regard, the assay was certainly very successful, as we are clearly able to distinguish an R316Q FTO mutant from wild-type FTO. Crucially, however, the sensitive and continuous nature of this fluorescence assay meant we were able to obtain some previously unknown kinetic information. Because FTO is implicated in obesity, is nutritionally regulated within the brain and utilizes 2-OG, a key metabolite in the citric acid cycle, as a co-substrate, it was certainly plausible that FTO could act as a sensor for intracellular metabolism. Thus we used our assay to examine the enzyme kinetics of FTO with regard to its usage of 2-OG, arriving at a 2-OG K m value for FTO of 2.88 μM. Since typical intracellular concentrations of 2-OG are measured to be more than 10-fold higher, at approximately 50-100 μM [19] , it is unlikely that the physiologocal role of FTO is to sense 2-OG. The 2-OG K m value for FTO appears to be in the similar region as for other dioxygenases such as PHD2 (prolyl hydroxylase domain-containing protein 2) (0.9 μM) [20] and HIF1α (hypoxia-inducible factor 1α) (10 μM) [21] .
High-throughput screening?
Another advantage of this fluorescence assay is its ability to be performed on a microlitre scale, thus making it amenable to a high-throughput screen for enhancers or inhibitors. The question, however, lies in whether FTO, given its ubiquitous expression, can even be considered a viable target? The severity of the phenotype seen in human and murine FTO deficiency clearly points to some fundamental role, particularly in early postnatal development [8, 17] . Yet, we have been able to use it to influence food intake by discretely manipulating its expression in certain regions of the brain [4] . We hypothesize that although FTO clearly has a broader biological function, it also has a role specifically within the hypothalamus to regulate food intake. So there is the age-old problem of selectivity and specificity.
A second question is whether one would screen for an enhancer or an inhibitor? Human genetic data indicate that although SNPs in intron 1 of FTO are unequivocally associated with obesity in multiple populations, it appears that loss of one functional copy of FTO in humans is compatible with being either lean or obese [9] . Mouse models of Fto deficiency, although far from being straightforward, have been a little more helpful in illuminating a role for FTO energy balance [4, [15] [16] [17] [18] . Mice homozygous for a targeted deletion in Fto display a complex phenotype [17] . They are postnatally growth retarded with decreased fat and lean body mass, and although are born with a normal body weight and at the expected Mendelian ratio, display 50 % lethality by the time of weaning. Fto − / − mice appear to display hyperphagia and increased energy expenditure when corrected for lean body mass [17] .
Mice overexpressing Fto showed a dramatic increase in food intake, resulting in a marked increase in body weight and fat mass when they were fed either chow or a high-fat diet [16] . Although the increase in weight with the overexpression of Fto seems consistent with Fto deficiency resulting in a 'lean' phenotype, the increase in food intake seen in these mice is not [16] . CNS (central nervous system)-specific Fto-deleted mice have now been generated [18] . Surprisingly, these brain-specific Fto-deficient mice recapitulate the phenotype of the whole-body knockouts, although this is yet to be exhaustively examined. This suggests that much of the function of Fto, including its link to the regulation of energy homoeostasis (and in keeping with the observations in [4] ), is mediated in the brain.
Physiological role?
As designed, the assay described in the present paper will only work to determine the ability of FTO to demethylate 3-meU [3, 5] , and not the recently described 6-meA [6] , as RNase A is only able to cleave after pyrimidines. It also does not address the question as to whether or not 3-meU is its endogenous substrate in vivo, or how this might play a role in energy homoeostasis. This was never our intention when we undertook this project. It is, however, useful to consider where 3-meU naturally occurs. As it turns out, in as far as it has been measured, 3-meU is found primarily in ribosomal RNA [22] . 6-meA, on the other hand, is found primarily in mRNA [23] .
Two other questions emerge regarding the utility of this assay. (i) Would there be any difference in measured activity if endogenous FTO and not recombinant FTO were used in the assay? One would imagine that if any post-translational modifications were critical to FTO activity, the endogenous FTO would give an increase in activity. We are currently addressing this question. (ii) What are the prospects of using this assay to test the activity of FTO in biological samples? There are two reasons why this is unlikely to work for this specific assay. First, there is the issue of getting the DNA-RNA hybrid reporter into the biological samples intact and, secondly, once in the cell or tissue, there is the impossibility of protecting the reporter from the action of endogenous RNases.
Conclusions
FTO, as we have discussed, influences the body weight of a large proportion of the human population, yet its physiological role remains unknown. Understanding the biology of FTO and its downstream actions could potentially reveal novel therapeutic targets in our battle against the increasing epidemic of obesity. Our novel high-throughput assay will allow us to rapidly and economically screen for any potential functional interaction candidate binding partners FTO may have, and will also allow us to revisit the library of naturally occurring human FTO mutations, with the potential to obtain further structure-function relations for FTO. Should it eventually prove appropriate, this assay would also lend itself to high-throughput screening for enhancers or inhibitors of FTO function.
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